OpenAI launches GPT-Rosalind, a restricted life sciences AI model that outperforms 95% of human experts in RNA sequence prediction and surpasses other AI on science benchmarks, with access limited to approved organizations like Amgen and Moderna due to misuse concerns.
OpenAI launches GPT-Rosalind, a frontier AI model purpose-built for life sciences that outperforms human experts above the 95th percentile on RNA sequence-to-function tasks, beats competitors on key benchmarks, and is now available in research preview for U.S. Enterprise customers through partnerships with Amgen, Moderna, and the Allen Institute.
AWS launches Amazon Bio Discovery, an AI-powered platform that designed nearly 300,000 novel antibody molecules in collaboration with Memorial Sloan Kettering Cancer Center, slashing drug discovery timelines from up to a year down to just weeks.
Anthropic acquires stealth AI biotech startup Coefficient Bio in a $400 million stock deal, bringing the 10-person team behind an AI-driven drug discovery platform into its health and life sciences division, accelerating the company's growing push into healthcare.
Eli Lilly signs a landmark $2.75 billion deal with AI drug pioneer Insilico Medicine, offering $115 million upfront to fast-track AI-generated drugs across multiple disease areas into global markets.
At MWC's 4YFN showcase, AI startups are proving real-world impact beyond frontier models, with Ultralytics hitting 2.5 billion inferences, Biorce raising $52 million for clinical trials, and NeuralTrust securing EU backing to protect enterprise AI systems from cyber threats.
Isomorphic Labs unleashes IsoDDE, a groundbreaking AI drug-discovery engine that outperforms open-source rivals in predicting drug-protein interactions, but scientists are raising concerns as the powerful DeepMind spin-off keeps its technology fully proprietary, blocking the broader research community from replicating or building on its breakthroughs.
NVIDIA launches a $1 billion AI drug discovery lab with pharmaceutical giant Lilly and expands its BioNeMo platform, partnering with major life sciences companies to automate scientific discovery through AI models that predict molecular structures and connect digital agents to robotic laboratory systems.
NVIDIA and Eli Lilly unveil a groundbreaking $1 billion AI co-innovation lab that promises to revolutionize drug discovery by creating a continuous learning system connecting physical laboratories with computational AI for round-the-clock experimentation and pharmaceutical development.
Utah becomes the first state to legally allow AI to autonomously renew prescriptions for chronic conditions through a partnership with platform Doctronic, while federal legislation proposes expanding AI prescribing authority nationwide.